Biological Processes Associated with Breast Cancer Clinical Outcome Depend on the Molecular Subtypes

By C. Desmedt, Benjamin Haibe-Kains, P. Wirapati, M. Buyse, D. Larsimont, Gianluca Bontempi, Mauro Delorenzi, M. Piccart, C. Sotiriou. Clinical Cancer Research, 2008

828 citations recorded by the source corpus.

Subfields: Cancer Research, Oncology

View Paper: https://www.semanticscholar.org/paper/123ef39bf12083ebdf8dbf9d43baed06aac3106f

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Cancer Research

In Oncology

Citations in the corpus

Tumor Metastasis: Molecular Insights and Evolving Paradigms (2011, neutral): “…assays are principally informative for the prognosis of patients within only certain subclasses of primary 286 Cell 147, October 14, 2011 ª2011 Elsevier Inc. breast tumors and fail to identify individuals with heightened risk who suffer from other subtypes of the disease (Desmedt et al., 2008).”
Pembrolizumab in Patients With Advanced Triple-Negative Breast Cancer: Phase Ib KEYNOTE-012 Study. (2016, background): “Gene expression profiling demonstrated an association between expression of immunomodulatory genes and better clinical outcomes in TNBC.(28) In addition, significant infiltration of TNBC tumors with tumor-infiltrating lymphocytes, which have been shown to have prognostic significance in TNBC, has be”
Cancer classification using the Immunoscore: a worldwide task force (2012, background): “Data based on immune signatures have established that a strong immune component is predictive of good response to chemotherapy in breast cancer [31-33], a tumor in which a high lymphocyte infiltrate is associated with higher response rate in neo-adjuvant therapy [34,35].”
Genefu: an R/Bioconductor package for computation of gene expression-based signatures in breast cancer (2016, background): “We previously demonstrated that the majority of prognostic signatures show similar performance despite limited genetic overlaps between them (Desmedt et al. , 2008; Wirapati et al. , 2008).”
The secret ally: immunostimulation by anticancer drugs (2012, background): “Along similar lines, an immunity-related gene signature was found to predict the response of patients with oestrogen receptor-negative breast cancer who were treated with anthracyclines or taxane”
A Pleiotropically Acting microRNA, miR-31, Inhibits Breast Cancer Metastasis (2009, neutral): “Such grade and subtype independence is quite surprising, because clinically utilized prognostic markers for breast cancer largely correlate with these parameters; furthermore, currently available markers do not identify a worse-prognosis group within the more aggressive basal-like or HER2 subtypes (”
A Living Biobank of Breast Cancer Organoids Captures Disease Heterogeneity. (2018, neutral): “…et al., 2017 http://bioconductor.org/packages/release/ bioc/html/sva.html PAM50 Parker et al., 2009 N/A SCMGENE Haibe-Kains et al., 2012 N/A SCMOD1 Desmedt et al., 2008 N/A IntClust Ali et al., 2014 https://cran.r-project.org/web/packages/ IntClust/index.html (Continued on next page) e2 Cell 172,…”
bc-GenExMiner: an easy-to-use online platform for gene prognostic analyses in breast cancer (2012, background): “(2) We tested genes whose prognostic significance at the RNA level has been proven for particular molecular subtypes: PLAU for HER2? and STAT1 for basal-like [17, 25].”
The immune contexture in human tumours: impact on clinical outcome (2012, background): “Data based on immune signatures have established that a strong immune cell component is predictive of a good response to chemotherapy in breast cance”
PD-L1 Expression in Triple Negative Breast Cancer (2014, neutral): “For TNBC, only the immune response module was associated with clinical outcome (5).”
GOBO: Gene Expression-Based Outcome for Breast Cancer Online (2011, positive): “These findings reinforce that prognostic gene signatures in breast cancer need to be evaluated in a subtypespecific manner in sufficiently large sample sets [18,19,22,49].”
Most Random Gene Expression Signatures Are Significantly Associated with Breast Cancer Outcome (2011, background): “Contrasting with this diversity, meta-analyses of several outcome signatures have shown that they have essentially equivalent prognostic performances [35,36], and are highly correlated with proliferation [7–8,37], a predictor of breast cancer outcome that has been used for decades [38–40].”